Semaglutide is a glucagon-like peptide-1 receptor agonist, approved and currently actively used worldwide for the treatment of type 2 diabetes mellitus and obesity. With the growing popularity of the drug, reports of both adverse and beneficial effects of the drug on mental health have become more frequent. The purpose of this study is to review the impact of semaglutide on mental health by collecting, analyzing, and synthesizing current scientific evidence. The authors conclude that currently there is no unequivocal opinion on this matter, which opens up new horizons for future research.
Authors
Rozhdestvenskaya, V A; Yuzbashyan, P G; Romanov, D V; Shchurenkov, A V; Kazaryan, P A; Sheyanov, A M; Zubacheva, E O; Fedyainova, I K
Keywords
GLP-1 agonistsaddictionalcohol dependenceanxietyautoaggressioncognitive functionsdepressiondiabetes mellitusobesitysemaglutidesuicidal behaviorweight loss